Loading...
Anti-VEGF agents in metastatic colorectal cancer (mCRC): are they all alike?
Bevacizumab is a monoclonal antibody that binds and neutralizes vascular endothelial growth factor (VEGF)-A, a key player in the angiogenesis pathway. Despite benefits of bevacizumab in cancer therapy, it is clear that the VEGF pathway is complex, involving multiple isoforms, receptors, and alternat...
Na minha lista:
| Hovedforfatter: | |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Dove Medical Press
2013
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3685399/ https://ncbi.nlm.nih.gov/pubmed/23807861 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CMAR.S45193 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|